Evaluation of Pegylated Liposomal Doxorubicin in the Treatment Of Both Platinum- and Paclitaxel-Refractory Epithelial Ovarian Cancer

Objective: Pegylated liposomal doxorubicin (PLD) is a stealth liposomal form of doxorubicin that has been approved for the treatment of patients with relapsed ovarian cancer. Previous studies have shown a response rate of about 25% in patients who had treatment failure with prior platinum- and/or pa...

Full description

Bibliographic Details

Published in:	Taiwanese Journal of Obstetrics & Gynecology
Main Authors:	Hao Lin, Chih-Wen Tseng, Hung-Yaw Chang, Hsien-Ming Lu, Yu-Che Ou, Chan-Chao Changchien
Format:	Article
Language:	English
Published:	Elsevier 2004-09-01
Subjects:	pegylated liposomal doxorubicin epithelial ovarian cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S1028455909600711